Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192150 · ClinicalTrials.gov registry record · Phase 3
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT03192150 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 246 participants.
The verdict
NCT03192150, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
Interventions
- OTHER Vehicle
- DRUG ISV-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2019-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03192150
The ClinicalTrials.gov registry entry for NCT03192150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03192150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03192150 about?
NCT03192150 is a clinical study titled "2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery". The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
What is the current status of trial NCT03192150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2018-01-03. Estimated completion is 2019-11-18.
What interventions are being tested in trial NCT03192150?
The interventions under investigation include: Vehicle (OTHER), ISV-305 (DRUG).
Who is sponsoring clinical trial NCT03192150?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.